Small Cap Gainers: ACET, RAAS, GHRS
5:23 pm Monday, December 06th, 2021
Adicet Bio Inc (NASDAQ:ACET): Announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of B-cell Non-Hodgkin’s Lymphoma. Three of four evaluable patients in the study, who were heavily pre-treated, achieved responses, including two complete responses and one partial response characterized by investigators as near complete response.
Cloopen Group Holding Ltd (NYSE:RAAS): Rebounds after pulling back by approx. 23% to hit new record lows on Friday. Cloopen Group Holding Limited, through its subsidiaries, provides cloud-based communications solutions in the People’s Republic of China.
GH Research PLC (NASDAQ:GHRS): Announced the “successful” outcome of the Phase 2 part of its Phase 1/2 clinical trial of GH001 in treatment-resistant depression, in which the primary endpoint was met with seven of eight patients in remission at day seven after dosing. Co also reported Q3 results and provided a business update; co’s cash position as of September 30 was $280.7 mln.
